TCR2 Therapeutics (TCRR) Receives a Hold From Mizuho Securities
TCR2 Therapeutics (TCRR) Was Downgraded to a Hold Rating at Mizuho Securities
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating
Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)
Jefferies Downgrades TCR2 Therapeutics to Underperform, Lowers Price Target to $3
Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Nurix Therapeutics (NRIX)
Truist Securities Downgrades TCR2 Therapeutics to Hold, Lowers Price Target to $3
Truist Securities Downgrades TCR2 Therapeutics to Hold From Buy, Cuts Price Target to $3 From $8
Wedbush Lowers TCR2 Therapeutics' Price Target to $2.18 From $4 on Heels of Adaptimmune Merger Announcement, Keeps Neutral Rating
TCR2 Therapeutics (TCRR) Was Downgraded to a Hold Rating at H.C. Wainwright
SVB Securities Keeps Their Hold Rating on TCR2 Therapeutics (TCRR)
Piper Sandler Adjusts Price Target on TCR2 Therapeutics to $10 From $8, Maintains Overweight Rating
TCR2 Therapeutics Analyst Ratings
Piper Sandler Maintains Overweight on TCR2 Therapeutics, Raises Price Target to $10
Mizuho Securities Remains a Buy on TCR2 Therapeutics (TCRR)
TCR2 Therapeutics Analyst Ratings
EF Hutton Initiates Coverage On TCR2 Therapeutics With Hold Rating, Announces Price Target of $2
HC Wainwright Trims Price Target on TCR2 Therapeutics to $13 From $14, Maintains Buy Rating
TCR2 Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13
No Data
No Data